Logo image of ZURA

ZURA BIO LTD (ZURA) Stock Fundamental Analysis

NASDAQ:ZURA - Nasdaq - KYG9TY5A1016 - Common Stock - Currency: USD

1.64  -0.04 (-2.38%)

After market: 1.63 -0.01 (-0.61%)

Fundamental Rating

2

ZURA gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 556 industry peers in the Biotechnology industry. ZURA has a great financial health rating, but its profitability evaluates not so good. ZURA does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

ZURA had negative earnings in the past year.
ZURA had a negative operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: ZURA reported negative net income in multiple years.
In the past 5 years ZURA always reported negative operating cash flow.
ZURA Yearly Net Income VS EBIT VS OCF VS FCFZURA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 0 -20M -40M -60M

1.2 Ratios

ZURA's Return On Assets of -36.08% is in line compared to the rest of the industry. ZURA outperforms 59.71% of its industry peers.
Looking at the Return On Equity, with a value of -44.96%, ZURA is in the better half of the industry, outperforming 67.81% of the companies in the same industry.
Industry RankSector Rank
ROA -36.08%
ROE -44.96%
ROIC N/A
ROA(3y)-30.27%
ROA(5y)N/A
ROE(3y)-48.3%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ZURA Yearly ROA, ROE, ROICZURA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 0 -20 -40 -60 -80 -100

1.3 Margins

ZURA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ZURA Yearly Profit, Operating, Gross MarginsZURA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024

More info and screens

7

2. Health

2.1 Basic Checks

ZURA has more shares outstanding than it did 1 year ago.
ZURA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ZURA Yearly Shares OutstandingZURA Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 20M 40M 60M
ZURA Yearly Total Debt VS Total AssetsZURA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

ZURA has an Altman-Z score of 0.21. This is a bad value and indicates that ZURA is not financially healthy and even has some risk of bankruptcy.
ZURA has a better Altman-Z score (0.21) than 62.59% of its industry peers.
ZURA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 0.21
ROIC/WACCN/A
WACCN/A
ZURA Yearly LT Debt VS Equity VS FCFZURA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 50M 100M

2.3 Liquidity

A Current Ratio of 8.19 indicates that ZURA has no problem at all paying its short term obligations.
ZURA has a Current ratio of 8.19. This is in the better half of the industry: ZURA outperforms 71.22% of its industry peers.
ZURA has a Quick Ratio of 8.19. This indicates that ZURA is financially healthy and has no problem in meeting its short term obligations.
ZURA has a better Quick ratio (8.19) than 71.40% of its industry peers.
Industry RankSector Rank
Current Ratio 8.19
Quick Ratio 8.19
ZURA Yearly Current Assets VS Current LiabilitesZURA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 50M 100M 150M

More info and screens

0

3. Growth

3.1 Past

ZURA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 57.65%, which is quite impressive.
EPS 1Y (TTM)57.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-850%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

ZURA is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -22.31% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-40.02%
EPS Next 2Y-21.55%
EPS Next 3Y-22.31%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ZURA Yearly EPS VS EstimatesZURA Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 -0.5 -1 -1.5 -2 -2.5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ZURA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ZURA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ZURA Price Earnings VS Forward Price EarningsZURA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ZURA Per share dataZURA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2

4.3 Compensation for Growth

A cheap valuation may be justified as ZURA's earnings are expected to decrease with -22.31% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-21.55%
EPS Next 3Y-22.31%

More info and screens

0

5. Dividend

5.1 Amount

ZURA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ZURA BIO LTD

NASDAQ:ZURA (7/25/2025, 8:00:02 PM)

After market: 1.63 -0.01 (-0.61%)

1.64

-0.04 (-2.38%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-08 2025-05-08/bmo
Earnings (Next)08-13 2025-08-13/bmo
Inst Owners70.81%
Inst Owner ChangeN/A
Ins Owners7.88%
Ins Owner Change0%
Market Cap101.47M
Analysts84.62
Price Target13.67 (733.54%)
Short Float %2.65%
Short Ratio1.87
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)9.67%
Min EPS beat(2)-17.47%
Max EPS beat(2)36.82%
EPS beat(4)1
Avg EPS beat(4)-24.64%
Min EPS beat(4)-106.68%
Max EPS beat(4)36.82%
EPS beat(8)4
Avg EPS beat(8)-47.46%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-3.3%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-20.21%
EPS NY rev (1m)0%
EPS NY rev (3m)-17.05%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.74
P/tB 0.74
EV/EBITDA N/A
EPS(TTM)-0.72
EYN/A
EPS(NY)-0.81
Fwd EYN/A
FCF(TTM)-0.55
FCFYN/A
OCF(TTM)-0.55
OCFYN/A
SpS0
BVpS2.23
TBVpS2.23
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -36.08%
ROE -44.96%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-30.27%
ROA(5y)N/A
ROE(3y)-48.3%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 1200%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 8.19
Quick Ratio 8.19
Altman-Z 0.21
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)57.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-850%
EPS Next Y-40.02%
EPS Next 2Y-21.55%
EPS Next 3Y-22.31%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-4.25%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-728.64%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-725.73%
OCF growth 3YN/A
OCF growth 5YN/A